LBT-3627 / Longevity Biotech - LARVOL DELTA

A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Longevity Biotech Australia Pty Ltd (subsidiary) | Trial completion date: Mar 2025 ➔ Oct 2025 | Trial primary completion date: Mar 2025 ➔ Oct 2025

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Longevity Biotech Australia Pty Ltd (subsidiary) | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: Longevity Biotech Australia Pty Ltd (subsidiary)

New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

Parkinson's Disease Inflammatory Biomarker Profiling (clinicaltrials.gov) - P=N/A | N=99 | Terminated | Sponsor: Longevity Biotech | Unknown status ➔ Terminated; COVID-19

Biomarker • Trial termination • CNS Disorders • Movement Disorders • Parkinson's Disease • TNFA

Parkinson's Disease Inflammatory Biomarker Profiling (clinicaltrials.gov) - P=N/A; N=134; Recruiting; Sponsor: Longevity Biotech; Enrolling by invitation ➔ Recruiting

Biomarker • Clinical • Enrollment status

A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson's Disease. (PubMed, Front Cell Neurosci) - "Herein, a vasoactive intestinal peptide receptor-2 (VIPR2) peptide agonist, LBT-3627, was developed as a neuroprotectant for PD-associated dopaminergic neurodegeneration...Taken together, these data provide the basis for the use of VIPR2 agonists as potent therapeutic immune modulating agents to restore Treg activity, attenuate neuroinflammation, and interdict dopaminergic neurodegeneration in PD. The data underscore an important role of immunity in PD pathogenesis."

Journal